Secondary Logo

Journal Logo


doi: 10.1097/PPO.0b013e3181ac6cf0

From the Department of Radiation Oncology, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Reprint: Andrea K. Ng, MD, MPH, 75 Francis St., ASB1-L2, Boston, MA 02115. E-mail:

In the March/April issue, the review by Dr Avrum Bluming and Carol Tavris entitled, “Hormone Replacement Therapy: Real Concerns and False Alarms,” requires that an additional sentence be added to the disclosure statement.

The new disclosure sentence is: Dr. Bluming wishes to disclose that he has received compensation in the past as an expert witness on behalf of Wyeth Pharmaceuticals (the maker of HT drugs Premarin and Prempro) to consult and advise on litigation.

In addition to the above change, please note there were also changes made to the References column of Table 1, which appears on page 94 of the article.



Also, on page 96, Table 2, the reference cited for the first 2003 entry should be 34, not 37.

Back to Top | Article Outline


Bluming AZ, Tavris C. Hormone replacement therapy: Real concerns and false alarms. Cancer J 2009;15:93–104.
© 2009 Lippincott Williams & Wilkins, Inc.